Vir and alnylam identify rnai therapeutic development candidate for the treatment of covid-19

Vir and alnylam identify rnai therapeutic development candidate, vir-2703 (aln-cov), targeting sars-cov-2 for the treatment of covid-19.alnylam pharmaceuticals inc - companies expect to start human clinical trials at or around year-end 2020.alnylam pharmaceuticals inc - plan to soon meet with fda to discuss a potential accelerated path for filing ind at or around year-end 2020.
ALNY Ratings Summary
ALNY Quant Ranking